1. Home
  2. EVH vs NGEN Comparison

EVH vs NGEN Comparison

Compare EVH & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evolent Health Inc

EVH

Evolent Health Inc

N/A

Current Price

$2.98

Market Cap

344.8M

ML Signal

N/A

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$4.07

Market Cap

317.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
EVH
NGEN
Founded
2011
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Other Consumer Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
344.8M
317.6M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
EVH
NGEN
Price
$2.98
$4.07
Analyst Decision
Strong Buy
Analyst Count
15
0
Target Price
$7.93
N/A
AVG Volume (30 Days)
3.1M
100.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$907,957,000.00
N/A
Revenue This Year
$33.03
N/A
Revenue Next Year
$16.03
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$3.73
52 Week High
$11.92
$5.93

Technical Indicators

Market Signals
Indicator
EVH
NGEN
Relative Strength Index (RSI) 44.63 40.23
Support Level $2.53 $3.76
Resistance Level $4.20 $4.44
Average True Range (ATR) 0.26 0.26
MACD 0.06 0.03
Stochastic Oscillator 42.68 30.00

Price Performance

Historical Comparison
EVH
NGEN

About EVH Evolent Health Inc

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: